+357 96 030922
info@marketpublishers.com

U.S. Vaccines Market Size, Share & Trends Analysis Report By Indication (Viral, Bacterial, Cancer Vaccines, Allergy), By Type (Subunit, Inactivated), By Payer Type, By Age Group, By Use Populations, By Usage/Administration Pattern, By Sales, And Segment Forecasts, 2026 - 2033

https://marketpublishers.com/r/UFECB9F9AD52EN.html
Date: April 2026
Pages: 150
Price: US$ 5,950.00 (Single User License)
ID: UFECB9F9AD52EN

Abstracts

The U.S. vaccines market size was estimated at USD 26.00 billion in 2025 and is projected to reach USD 40.19 billion by 2033, growing at a CAGR of 5.40% from 2026 to 2033. The U.S. vaccines market is driven by rapid advancements in vaccine technologies and platform innovation.

The adoption of mRNA, recombinant, and vector-based approaches is accelerating the development of more effective and targeted vaccines across multiple disease areas. Continuous improvements in formulation, adjuvants, and delivery systems are enhancing immune response and overall product performance. Increasing focus on precision-based immunization is supporting the development of vaccines tailored to specific populations and disease risks.

Advancements in manufacturing technologies are improving scalability, reducing production timelines, and ensuring consistent quality. Strong research pipelines and faster development cycles are enabling quicker responses to emerging health threats. These factors are strengthening innovation capabilities and supporting sustained growth across the U.S. vaccines market. For instance, in January 2026, the U.S. Department of Health and Human Services announced that the Centers for Disease Control and Prevention had accepted recommendations to revise the U.S. childhood immunization schedule following a Presidential Memorandum issued on December 5, 2025. The

scientific assessment reviewed immunization practices across 20 peer-developed nations and found that, in 2024, the United States provided protection against 18 diseases, compared to Denmark, which immunized children against 10 diseases. The analysis also indicated that the U.S. recommended more childhood vaccines and more than twice as many doses as some European countries, while retaining three fully insured immunization categories without cost sharing.

Growing demand for adult immunization is a key factor supporting market expansion in the United States. Rising prevalence of infectious diseases among aging populations is increasing the need for vaccines across multiple indications and risk groups. Higher awareness of preventive healthcare is encouraging routine vaccination among adults, including those with chronic conditions. Expansion of vaccination access through pharmacies, clinics, and workplace programs is improving convenience and uptake. Increasing incidence of respiratory infections such as influenza and respiratory syncytial virus is driving seasonal vaccine demand across regions. A longer life expectancy reinforces the importance of ongoing immunization beyond early life stages. For instance, in October 2025, the Centers for Disease Control and Prevention released an updated adult immunization schedule for individuals aged 19 years and older, covering four age cohorts, 1926 years, 2749 years, 5064 years, and 65 years and above. The schedule recommended one or more doses of the COVID-19 vaccine, one influenza dose annually, a three-dose tetanus, diphtheria, and pertussis primary series followed by one booster every 10 years and one additional dose during each pregnancy, as well as one respiratory syncytial virus vaccine dose for adults aged 5074 years and those aged 75 years or older, while hepatitis B vaccination was recommended through 59 years of age. These structured dosing intervals reinforced sustained adult vaccine demand and long-term revenue stability.

The market is further driven by portfolio expansion and evolving vaccination strategies across disease areas. Increasing development of combination vaccines is improving convenience, reducing the number of doses, and enhancing patient compliance. Regular updates in vaccine formulations are addressing emerging variants and changing epidemiological patterns across populations. Expansion into new therapeutic areas, including oncology and personalized vaccines, is creating additional growth opportunities. Improvements in supply chain systems are supporting efficient distribution, storage, and availability across healthcare settings. Increased collaboration across research networks is accelerating innovation and clinical development. For instance, in January 2026, Health Policy Watch reported that U.S. health authorities implemented a major revision to the childhood immunization schedule, reducing the number of diseases covered by routine vaccination from 17 to 11 and removing universal recommendations for six vaccines, including those for rotavirus, influenza, meningococcal disease, hepatitis A, hepatitis B, and respiratory syncytial virus. The revision also reduced the human papillomavirus vaccination requirement from two doses to one and followed a December 5, 2025 directive to review national practices against peer nations such as Denmark, Japan, Australia, Canada, and the United Kingdom, which recommended vaccines for 10, 14, and 15 diseases, respectively. Previous guidance indicated that children in the United States could receive approximately 35 to 36 doses across 18 years, while respiratory syncytial virus alone accounted for about 80,000 pediatric hospitalizations annually, highlighting the significant public health and market implications of schedule changes.

U.S. Vaccines Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. vaccines market report based on indication, type, payer type, age group, use populations, usage/administration pattern, and sales:

- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Viral Vaccines
    - Hepatitis
    - Influenza
    - HPV
    - MMR
    - Rotavirus
    - Herpes Zoster
    - Japanese Encephalitis
    - RSV
    - Others

+357 96 030922
info@marketpublishers.com

Bacterial Vaccines

- Meningococcal Diseases
- Pneumococcal Diseases
- DPT
- Others

Cancer Vaccines

Allergy Vaccines

Others

Type Outlook (Revenue, USD Million, 2021 - 2033)

Subunit Vaccines

- Recombinant Vaccines
- Conjugate Vaccines
- Toxoid Vaccines

Inactivated

Live Attenuated

mRNA Vaccines

Viral Vector Vaccines

Payer Type Outlook (Revenue, USD Million, 2021 - 2033)

Public Payer

Medicare

Medicaid

Federal Programs

Private Payers

Commercial Insurance Plans

Workplace Programs

Out-of-Pocket / Self-Pay

Others

Age Group Outlook (Revenue, USD Million, 2021 - 2033)

Pediatrics (0-17 years)

Adults (18-64 years)

Elderly (65+ years)

Use Populations Outlook (Revenue, USD Million, 2021 - 2033)

Workplace

Schools

Travelers

Military & Special Occupations

Others

Usage/Administration Pattern Outlook (Revenue, USD Million, 2021 - 2033)

Seasonal Vaccines

+357 96 030922
info@marketpublishers.com

Year-Round Vaccines

Others

Sales Outlook (Revenue, USD Million, 2021 - 2033)

Tender-Based

Direct Sales to Providers

This report can be delivered to the clients within 3 Business Days

Market Publishers
+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 7. U.S. VACCINES MARKET: INDICATION BUSINESS ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: U.S. Vaccines Market Size, Share & Trends Analysis Report By Indication (Viral, Bacterial, Cancer Vaccines, Allergy), By Type (Subunit, Inactivated), By Payer Type, By Age Group, By Use Populations, By Usage/Administration Pattern, By Sales, And Segment Forecasts, 2026 - 2033

Product link: https://marketpublishers.com/r/UFECB9F9AD52EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/UFECB9F9AD52EN.html